Profile: China Biologic Products Holdings Inc (CBPO.O)
12 Nov 2018
China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.
The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC). The Company offers human albumin for the treatment of shock caused by blood loss trauma or burn, raised intracranial pressure caused by hydrocephalus or trauma, edema or ascites caused by hepatocirrhosis and nephropathy, prevention and treatment of low-density-lipoproteinemia, and neonatal hyperbilirubinemia. It offers human immunoglobulin and IVIG for the treatment of original immunoglobulin deficiency, such as X chain low immunoglobulin, familiar variable immune deficiency, immunoglobulin G secondary deficiency, secondary immunoglobulin deficiency, such as infection and newborn sepsis, and auto-immune deficiency diseases, such as original thrombocytopenia purpura or kawasaki disease. It offers human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis. It offers human rabies immunoglobulin for passive immunity from bites or claws by rabies or other infected animals. It offers human tetanus immunoglobulin for the prevention and therapy of tetanus. It offers placenta polypeptide for the treatment for cell immunity deficiency diseases, viral infection and leucopenia caused by various reasons, and also in postoperative healing. It offers Factor VIII for the treatment for coagulopathies, such as hemophilia A and increased concentration of coagulation factor VIII. It offers PCC for the treatment of congenital and acquired clotting factor II, VII, IX, X deficiency, such as Hemophilia B, excessive anticoagulant and vitamin K deficiency.
The Company's products under development include Human fibrinogen, Immune Globulin Intravenous (Human), Caprylate/Chromatography Purified and 20 nanometers (nm) virus filtration, Human Antithrombin III (concentration), Human coagulation factor IX, Human Cytomegalovirus Immunoglobulin and Human Fibrin Sealant. It is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; Immune Globulin Intravenous (Human) for the treatment for original immunoglobulin deficiency; secondary immunoglobulin deficiency and auto-immune deficiency diseases; Human Antithrombin III (concentration) for the treatment for hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and thromboembolism; Human coagulation factor IX for the prevention and control of bleeding in patients suffering from hemophilia B; Human Cytomegalovirus Immunoglobulin for prophylaxis and treatment of cytomegalovirus (CMV) infection, especially for the prevention of active virus replication for patients in immunosuppression, such as organ transplantation patients, and Human Fibrin Sealant as an adjunct to hemostasis.
The Company competes with China National Biotec Group, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., Shanxi Kangbao Biological Product Co., Ltd. and Jiangxi Boya Bio Pharmaceutical Co., Ltd.
China Biologic Products Holdings Inc
BEIJING BEJ 100125
Company Web Links
- China Biologic rejects $3.9 billion bid from former CEO
- UPDATE 3-China Biologic rejects $3.9 bln bid from former CEO
- China Biologic rejects former CEO-led consortium's offer
- China Biologic gets $3.9 billion offer from former CEO-led consortium
- UPDATE 2-China Biologic gets $3.9 bln offer from former CEO-led consortium